NCT02317393

Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy

A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Centre Francois Baclesse · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the contribution of the imaging to the expression of intégrines αvβ3 for the characterization of the residual masses of non-seminoma tumors at the end of chemotherapy. The investigators hope that the results of this first stage of the clinical trial come to consolidate the preclinical results obtained by the investigators team to characterizing the interest and the strong contribution of the use of a tracer resting on the expression of αvβ3 integrine for the diagnosis of simple necrosed mass at the end of the treatment of a non-seminoma tumor, so allowing to defer a surgery to about 40 % of the patients.

Conditions

• Non-seminomatous Germ Cell Tumors
• Metastasis

Interventions

Type	Name	Description
OTHER	K5-RGD PET	Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
OTHER	FDG	Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy

Timeline

• Start date: 2014-12-01
• Primary completion: 2020-03-01
• Completion: 2020-03-01
• First posted: 2014-12-16
• Last updated: 2020-07-09

Locations

5 sites across 1 country: France